Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
Área temáticas
Farmacología y terapéutica(3)
Bioquímica(1)
Enfermedades(1)
Fisiología y materias afines(1)
Medicina y salud(1)
Área de conocimiento
Medicamento(2)
Origen
scopus(3)
CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
ArticleAbstract: The variability in the antipsychotic response is, to some extent, genetically determined. Several stPalabras claves:CYP2D6, EFFECTIVENESS, MDR1, pharmacogenetics, Risperidone, SchizophreniaAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusEvaluating a newly developed pharmacogenetic array: Screening in a Spanish population
ArticleAbstract: Aims: How genes affect the response in a patient to a given medication is still poorly understood; tPalabras claves:accuracy, CYP2D6, PHARMAChip array ®, pharmacogenetics, sensitivity, SLC6A4, Specificity, successful genotyping rateAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Gomez-Dominguez B., Lopez-Rodriguez R., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusUse of pharmacogenetics in bioequivalence studies to reduce sample size: An example with mirtazapine and CYP2D6
ArticleAbstract: In bioequivalence studies, intra-individual variability (CV w) is critical in determining sample sizPalabras claves:bioequivalence, Cost, CYP2D6, Genotypes, intra-individual, variabilityAutores:Abad-Santos F., Adrián LLerena, Carcas-Sansuan A., Dorado P., Estévez-Carrizo F.E., González-Vacarezza N., Penãs-Lledó E.M.Fuentes:scopus